A 33-year-old man after sudden cardiac arrest as a first manifestation of Brugada syndrome (RCD code: V‑1A.1)

Katarzyna Holcman, Paweł Rubiś, Sylwia Wiśniowska‑Śmiałek, Barbara Biernacka‑Fiałkowska, Marta Hlawaty, Agata Leśniak–Sobelga, Grzegorz Karkowski, Jacek Bednarek, Jacek Lelakowski, Magdalena Kostkiewicz, Piotr Podolec

Full Text:

PDF

Abstract


Brugada syndrome is an autosomal dominant genetic disease with variable expression characterized by abnormal electrocardiographic findings – right bundle branch block and ST-segment elevation in the anterior precordial leads, without evidence of structural heart disease. Individuals affected by the disease have an increased risk of ventricular tachyarrhythmias and sudden cardiac death (SCD). We present a case of a 33-year old man who was admitted to cardiology department after sudden cardiac arrest due to ventricular fibrillation. Evaluation for a structural heart disease was negative and routine tests did not reveal the cause of cardiac arrest. Retrospective evaluation of the patient electrocardiograms showed changes consistent with Brugada type 2 pattern that were variable over time. Performed pharmacological challenge with sodium channel blocker – ajmaline – provided an ambiguous result. Nevertheless, the patient was qualified for an implantable cardioverter defibrillator implantation as a secondary SCD prophylaxis. He underwent the procedure without complications and was discharged home in good general condition without symptoms.

Keywords


rare disease; electrocardiography; ajmaline challenge; ventricular arrhythmias; implantable cardioverter‑defibrillator

References


Antzelevitch C, Brugada P, Borggrefe M, et al: Brugada syndrome: Report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 2005; 111: 659.

Wilde AA, Antzelevitch C, Borggrefe M, et al. Proposed diagnostic criteria for the Brugada syndrome. Eur Heart J 2002; 23:1648.

Bayés de Luna A, Brugada J, Baranchuk A, et al. Current electrocardiographic criteria for diagnosis of Brugada pattern: a consensus report. J Electrocardiol 2012; 45: 433.

Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal 2015; 36: 2793–2867.

Fowler SJ, Priori SG. Clinical spectrum of patients with a Brugada ECG. Curr Opin Cardiol 2009; 24: 74–81.

Matsuo K, Akahoshi M, Nakashima E, et al. The prevalence, incidence and prognostic value of the Brugadatype electrocardiogram: a population based study of four decades. J Am Coll Cardiol 2001; 38: 765.

Di Diego JM, Cordeiro JM, Goodrow RJ, et al. Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation 2002; 106:2004.

Priori SG, Napolitano C, Gasparini M, et al. Natural history of Brugada syndrome: insights for risk stratification and management. Circulation 2002; 105:1342–1347.

Fauchier L, Isorni MA, Clementy N, et al. Prognostic value of programmed ventricular stimulation in Brugada syndrome according to clinical presentation: an updated meta-analysis of worldwide published data. Int J Cardiol 2013;168: 3027–3029.

Brugada P. Brugada syndrome: More than 20 years of scientific excitement. J Cardiol. J Cardiol 2016; 67(3): 215–220.

Brugada P. Commentary on the Brugada ECG pattern: a marker of channelopathy, structural heart disease, or neither? Toward a unifying mechanism of the Brugada syndrome. Circ Arrhythm Electrophysiol 2010; 3(3): 280–282.

Watanabe H, Koopmann TT, Scouarnec SL, et al: Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008; 118(6): 2260–2268.

Chen Q, Glenn E, Zhang D, et al: Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392: 293.

Kapplinger JD, Tester DJ, Alders M, et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010; 7: 33– 46.

London B, Michalec M, Mehdi H, et al. Mutation in glycerol3phosphate dehydrogenase 1 like gene (GPD1L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007; 116: 2260.

Antzelevitch C, Pollevick GD, Cordeiro JM, et al. Loss of function mutations in the cardiac calcium channel underlie a new clinical entity characterized by ST segment elevation, short QT intervals, and sudden cardiac death. Circulation 2007; 115: 442.

Bonow RO, Mann DL, Zipes DP, Libby P, eds. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, PA: Elsevier Saunders; 2012.

Morita H, Zipes DP, Wu J. Brugada syndrome: insights of ST elevation, arrhythmogenicity, and risk stratification from experimental observations. Heart Rhythm. 2009; 6: 34–43.

Priori SG, Napolitano C, Gasparini M, et al. Clinical and genetic heterogeneity of right bundle branch block and ST segment elevation syndrome: A prospective evaluation of 52 families. Circulation 2000; 102: 2509.

Brugada R, Brugada J, Antzelevitch C, et al. Sodium channel blockers identify risk for sudden death in patients with ST segment elevation and right bundle branch block but structurally normal hearts. Circulation 2000; 101: 510.

Ruta J, Kawiński J, Ptaszyński P, et al. Nieprawidłowe ustawienie filtrów czy zespół Brugadów? Kardiologia Polska 2013; 71(11): 1192–1193.

Wichter T1, Matheja P, Eckardt L, et al: Cardiac autonomic dysfunction in Brugada syndrome. Circulation. 2002; 105(6): 702–706.




DOI: http://dx.doi.org/10.20418%2Fjrcd.vol2no7.221

Refbacks

  • There are currently no refbacks.
Journal of Rare Cardiovascular Diseases (JRCD)
John Paul II Hospital in Kraków, 80 Prądnicka Str., 31-202 Kraków, Poland
Phone: +48 (12) 614 33 99, +48 (12) 614 34 88 Fax: +48 (12) 614 34 88
e-mail: rarediseases@szpitaljp2.krakow.pl
Published by SoftQ sp. z o.o.
ul. Oleandry 2, 30-063 Kraków, Poland
Phone: +48 (12) 444 1650 Fax: +48 (12) 444 1659
e-mail: softq@softq.pl